

Center for Vaccine  
Ethics and Policy



**Vaccines and Global Health: The Week in Review**  
**30 November 2024 :: Issue 777**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

## ***Milestones, Perspectives***

.....  
.....

### **mPox – PHEIC**

<https://www.who.int/emergencies/situations/mpox-outbreak>

#### **Second meeting of the International Health Regulations (2005) Emergency Committee regarding the upsurge of mpox 2024**

28 November 2024 *Statement*

The Director-General of the World Health Organization (WHO) is hereby transmitting the report of the second meeting of the International Health Regulations (2005) (IHR) Emergency Committee (Committee) regarding the upsurge of mpox 2024, held on Friday 22 November 2024, from 12:00 to 17:00 CET.

Notwithstanding some progress towards controlling the spread of mpox resulting from national and international response efforts, **the Committee noted the rising number and continuing geographic spread of mpox cases**, especially those due to monkeypox virus clade Ib infection; the operational challenges in the field in need of stronger national commitments; as well as the need to mount and sustain a cohesive response across countries and partners.

**The Committee advised that the event continues to meet the criteria of a public health emergency of international concern (PHEIC)** and provided its views regarding the proposed temporary recommendations.

The WHO Director-General expresses his most sincere gratitude to the Chair, Members, and Advisors of the Committee. **The WHO Director-General concurs with the advice of the Committee that the event continues to constitute a PHEIC** for the reasons detailed in the proceedings of the meeting below, and issues revised temporary recommendations in relation to this PHEIC, which are presented at the end of this document.

*...Conclusion*

**The Committee reiterated its concern regarding the continuing spread of MPXV and uncertainties ensuing, and the effectiveness and efficiency of the response at the local level.** The Committee underscored the need for the sustained commitment by national authorities in focusing efforts and resources at the local level to interrupt MPXV transmission, as well as the role of coordinated international cooperation in supporting and complementing such efforts in a synergistic manner. Therefore, the Committee considers that the determination by the WHO Director-General that the upsurge of mpox still constitutes a PHEIC would be warranted.

.....  
.....

### **Polio – PHEIC**

#### **Polio this week - 27 Nov 2024**

##### ***Headlines***

- The GPEI wishes to express our deep shock and sympathy at the tragic and sudden passing of AFRO Regional Director-elect Dr Faustine Ndugulile. Our thoughts and prayers are at this tragic time with his family, friends, our colleagues in AFRO and the people of Tanzania.

- New data published in *Vaccines* scientific journal this week shows significantly reduced risk of variant type 2 poliovirus (cVDPV2) emergence from novel oral polio vaccine type 2 (nOPV2), compared with monovalent oral polio vaccine type 2 (mOPV2). The research evaluated data from OPV2 vaccination campaigns held between May 2016 to August 2024, and findings are consistent with accumulated clinical and field evidence of nOPV2's enhanced genetic stability. [More](#).
- **The Global Certification Commission for the Eradication of Poliomyelitis (GCC) convened in Geneva, Switzerland, last week**, to review latest global epidemiology, new action plans including of the currently-being-developed Global Polio Surveillance Action Plan (GPSAP), planning for bivalent OPV cessation, containment and post-certification, and received a brief on the GPEI Strategy extension. The Commission's report, once published, will be made available at [www.polioeradication.org](http://www.polioeradication.org).

#### **Summary of new polioviruses this week, cases and positive environmental isolates:**

- Pakistan: six WPV1 cases and 24 WPV1-positive environmental samples
- Algeria: one cVDPV2-positive environmental sample
- Nigeria: one cVDPV2-positive environmental sample

.....  
 .....

## **AIDS**

### **WORLD AIDS DAY REPORT 2024 – TAKE THE *RIGHTS* PATH TO END AIDS**

*The world now has the means to end AIDS as a public health threat by 2030.*

UNAIDS, Nov 2024 :: 128 pages

PDF: [https://www.unaids.org/sites/default/files/media\\_asset/take-the-rights-path-to-end-aids\\_en.pdf](https://www.unaids.org/sites/default/files/media_asset/take-the-rights-path-to-end-aids_en.pdf)

#### *INTRODUCTION*

**The world's decades-long response to HIV is at an inflection point.** The 2024 Joint United Nations Programme on HIV/AIDS (UNAIDS) global report, *The Urgency of Now: AIDS at a Crossroads*, demonstrated that the world now has the means to end AIDS as a public health threat by 2030 (1).

Midway to the 2025 milestone set at the United Nations General Assembly in June 2021, the global HIV response has moved closer to the goal of ending AIDS as a public health threat by 2030, a commitment enshrined in the Sustainable Development Goals (SDGs). Fewer people acquired HIV in 2023 than at any point since the late 1980s. Almost 31 million people were receiving lifesaving antiretroviral therapy in 2023, a public health success that has reduced the numbers of AIDS-related deaths to their lowest level since the peak in 2004.

Despite these successes, **the world is currently not on track to end AIDS as a public health threat by 2030. In 2023, 9.3 million [7.4 million–10.8 million] people living with HIV were still not receiving antiretroviral therapy and 1.3 million [1.0 million–1.7 million] people newly acquired HIV.**

In the regions where numbers of new HIV infections are growing the fastest, only very slow progress is being made in scaling up pre-exposure prophylaxis (PrEP). These regions also lag behind sub-Saharan Africa in progress towards meeting the 95–95–95 HIV testing and treatment targets. Coverage of prevention services among the populations at greatest risk of HIV is far too low—typically at less than 50%. **In at least 28 countries, the number of new HIV infections is on the rise, and a growing resource gap imperils the important progress made to date in the global HIV response.**

**At this historic crossroads, the path the world takes—towards ending AIDS, or towards a future of needless illness, death and unending costs—depends on political will.**

.....

**The central role of human rights in the global HIV response**

Many people consider the creation of UNAIDS in 1996 as marking a starting point for the modern global HIV response. Recognizing that efforts to address the HIV pandemic needed to extend well beyond the health sector, HIV stakeholders purposely established a multisectoral United Nations joint programme to galvanize actions at the global, regional and country levels to respond to HIV and AIDS, which at the time was increasing exponentially and erasing decades of development gains, but receiving only limited attention.

Community and civil society organizations led the way in demanding that the international community ground the response to HIV in human rights principles. Placing people and human rights at the centre of the global HIV response was, therefore, a defining principle of UNAIDS from its outset. As one of its very first steps, in 1996 UNAIDS joined with the Office of the United Nations High Commissioner for Human Rights to develop the International Guidelines on HIV/AIDS and Human Rights. Following consultations with international experts on health and human rights, the International Guidelines were amended in 2002 and consolidated in 2006 (4).

At a time when many countries and stakeholders were uncertain as to how best to address a spiralling health challenge, the International Guidelines provided a roadmap for aligning national responses with human rights commitments. The International Guidelines advised: “Public health interests do not conflict with human rights. On the contrary, it has been recognized that when human rights are protected, fewer people [acquire HIV] and those living with HIV and their families can better cope with HIV and AIDS” (4).

Human rights have continued to guide and inspire the global HIV response—from the global movement for universal access to affordable HIV treatment, to focused efforts to remove punitive laws targeting people living with HIV, women and girls, and people from key populations, to the 10–10–10 social enabler targets for 2025.

SOCIAL ENABLERS		
10–10–10 targets for removing social and legal impediments towards an enabling environment limiting access or utilization of HIV services		
Less than 10% of countries have punitive legal and policy environments that deny or limit access to services.	Less than 10% of people living with HIV and people from key populations experience stigma and discrimination.	Less than 10% of women, girls, people living with HIV and people from key populations experience gender inequality and violence.

.....

**[UNAIDS report shows that upholding human rights is vital for ending the AIDS pandemic](#)**

GENEVA, 26 November 2024— Ahead of World AIDS Day (1 December), a new report by UNAIDS shows that the world can meet the agreed goal of ending AIDS as a public health threat by 2030 – but only if leaders protect the human rights of everyone living with and at risk of HIV. The report's message is summed up in its title: "Take the rights path to end AIDS".

**"Despite huge progress made in the HIV response, human rights violations are still preventing the world from ending AIDS,"** said Winnie Byanyima, Executive Director of UNAIDS. "When girls are denied education; when there is impunity for gender-based violence; when people can be arrested for who they are, or who they love; when a visit to health services is dangerous for people because of the community they are from—the result is that people are blocked from being able to access HIV services that are essential to save their lives and to end the AIDS pandemic. To protect everyone's health, we need to protect everyone's rights."...

**The report includes ten guest essays from leaders in the global AIDS response** including: Elton John; Archbishop of Cape Town, Thabo Makgoba; Irish President, Michael D. Higgins; United Nations High Commissioner for Human Rights, Volker Türk; and former President of the International AIDS Society, Adeeba Kamarulzaman.

Elton John, in his essay in the UNAIDS report, writes, "I know the feeling of shame and what it can do. As long as HIV is seen as a disease for the 'others', not so-called 'decent people', AIDS will not be beaten. Science, medicine and technology may be the 'what' in ending AIDS, but inclusion, empathy and compassion are the 'how'."

President Michael D. Higgins, in his essay, writes, **"Ensuring that the fullness of human rights is achieved is a practical necessity crucial if we are to rid the world of the scourge of AIDS. Fulfilling the pledge to end AIDS as a public health threat is a political and financial choice. The time to choose the correct path is long overdue."**...

.....  
.....

## **World Trade Organisation – Vaccine Classification**

### **Members endorse thematic sessions workplan, welcome progress on vaccine classification**

20 November 2024

At a meeting of the Committee on Market Access (CMA) on 19-20 November, members agreed to wrap up a series of thematic sessions on supply chain resilience. **They also welcomed progress on a joint effort by the World Customs Organization (WCO), World Health Organization (WHO) and the WTO to establish new tariff headings for vaccines**, a move which will help facilitate the implementation of relevant trade and public health policies. Members also addressed a high number of trade concerns...

#### ***WHO-WCO-WTO proposal for new HS codes on vaccines***

The Committee heard a report from the World Customs Organization (WCO) about recent developments at the latest sessions of the WCO's Harmonized System Committee (HSC) and Review Sub-Committee (RSC) relating to the Committee's communication on the classification of COVID-19 essential goods. The report noted the Committee's interest in making the HS classification more granular in respect of vaccines.

**Currently, there is only one subheading for "vaccines for human medicine", under which all vaccines traded today are classified.** This has complicated the adoption of targeted trade policy

measures and the collection of international trade statistics, particularly during the COVID-19 pandemic.

The HS Review Sub-Committee continued the examination of a revised proposal from the World Health Organization, which was developed in collaboration with the WTO and the WCO secretariats, to **streamline the number of new subheadings that are being proposed to cover all major disease groups for which vaccination is important. According to the proposal, a new heading 3007, "vaccines for human medicine", will be created in [HS 2028](#), under which seven new positions are included. This will include several HS subheadings naming a total of 36 vaccines against specific diseases...**

The interim Chairperson said she agreed that the collaboration among the WCO, WHO and WTO was instrumental in achieving the approval of the vaccine proposal and represented a tangible outcome. **Improving the granularity of vaccines in the next version of the HS will render their trade flow more transparent and will facilitate the implementation of trade but also public health policies, she said. This will contribute among other things to a more effective response in future global health crises,** she added.

.....

### **[WHO, WIPO, WTO to host symposium on boosting manufacturing for non-communicable diseases](#)**

20 November 2024

The World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the WTO will hold the 11th Trilateral Technical Symposium on "Strengthening Manufacturing Capacities to Respond to the Non-Communicable Diseases Burden" on 13 December 2024 at the WTO. The deadline for registration is 9 December.

.....

.....

### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....

.....

### **WHO & Regional Offices [to 30 Nov 2024]**

<https://www.who.int/news>

*Selected News/Announcements/Statements*

29 November 2024 *News release*

### **[New report highlights need for sustained investment in infection prevention and control programmes](#)**

28 November 2024 *Statement*

### **[Second meeting of the International Health Regulations \(2005\) Emergency Committee regarding the upsurge of mpox 2024](#)**

26 November 2024 *News release*

## [International Pathogen Surveillance Network announces first recipients of grants to better understand disease threats](#)

.....

### **WHO Regional Offices**

*Selected Press Releases, Announcements*

#### **WHO African Region AFRO**

:: 29 November 2024

#### **Availability of antiretroviral treatment bolsters HIV/AIDS control in Equatorial Guinea**

:: 27 November 2024

#### **Saddened by the passing of Dr Faustine Ndugulile, Regional Director-elect**

:: 26 November 2024

#### **Addressing the challenges of antimicrobial resistance in Africa**

#### **WHO Region of the Americas PAHO**

:: 28 Nov 2024

#### **On World AIDS Day, PAHO launches Better with PrEP campaign**

The initiative aims to promote greater awareness and expand access to the HIV prevention pill, whose adoption in Latin America and the Caribbean remains limited. Washington, D.C., November 28, 2024 (PAHO).— In the context of World AIDS Day (December 1), the Pan American Health Organization (PAHO) has launched the "Better with PrEP" campaign,...

:: 26 Nov 2024

#### **PAHO calls on countries of the Americas to maintain Mpox surveillance and genomic sequencing**

Washington D.C., November 26, 2024 (PAHO) – The Pan American Health Organization (PAHO) continues to urge countries of the Americas to maintain mpox surveillance, including laboratory detection and genomic sequencing of confirmed cases, following the detection of a Clade I variant case for the first time in the Region, in the United States of...

#### **WHO South-East Asia Region SEARO**

*No new digest content identified.*

#### **WHO European Region EURO**

:: 29 November 2024 *News release*

#### **New WHO/Europe fact sheet highlights worrying post-COVID trends in childhood obesity**

:: 28 November 2024 *Media release*

#### **Poliovirus detections in European Region underscore importance of vaccination and vigilance**

:: 28 November 2024 *Media release*

Under- and late diagnosis of HIV is holding back progress to end AIDS in the European Region

#### **WHO Eastern Mediterranean Region EMRO**

#### **WHO signs a €3.4 million agreement with the Government of Germany to sustain lifesaving health services in Yemen**

27 November 2024

#### **WHO Western Pacific Region**

:: 27 November 2024

#### **Viet Nam offers HIV self-testing online to boost equitable access to health care**

.....



## **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

*No new digest content identified.*

.....

## **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new digest content identified.*

.....

## **Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

**Vol. 99, 48 [full issue]**

PDF: <https://iris.who.int/bitstream/handle/10665/379600/WER9947-eng-fre.pdf>

:: Schistosomiasis and soiltransmitted helminthiasis: progress report, 2023

.....

## **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

30 November 2024

### **[WHO guidelines for malaria](#)**

*Overview*

The *WHO guidelines for malaria* bring together the Organization's most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate [online platform](#)...

This version of the Guidelines includes an updated recommendation for malaria vaccines, new recommendations on the use of near-patients qualitative and semiquantitative G6PD tests to guide anti-relapse treatment of *P. vivax* and *P. ovale*, updated recommendations on primaquine and the recommendation on the use of tafenoquine. It replaces the versions published on 16 February 2021, 13 July 2021, 18 February 2022, 31 March 2022, 3 June 2022, 25 November 2022, 14 March 2023 and 16 October 2023.

29 November 2024

### **[Report of the third meeting of the WHO Technical Advisory Group on Arboviruses \(TAG-Arbovirus\): hybrid...](#)**

29 November 2024

### **[Global report on infection prevention and control 2024](#)**

*Overview*

Health care-associated infections (HAIs) affect patients and health systems every day, causing immense suffering, driving higher health-care costs and hampering efforts to achieve high-quality care for all. HAIs are often difficult to treat, are the major driver of antimicrobial resistance (AMR) and cause premature deaths and disability. The COVID-19 pandemic, as well as outbreaks of Ebola, Marburg and mpox are the most dramatic demonstrations of how pathogens can spread rapidly and be amplified in health care settings. But HAIs are a daily threat in every hospital and clinic, not only during epidemics and pandemics. Lack of water, sanitation and hygiene (WASH) in health care settings not only affects



the application of infection prevention and control (IPC) best practices but also equity and dignity among both those providing and receiving care. However, there is strong evidence that a large proportion of these infections could be prevented with IPC measures and basic WASH services, with a high return on investment. This second global report on IPC provides updated evidence on the harm caused to patients and health workers by HAIs and AMR, and presents an updated global analysis of the implementation of IPC programmes at the national and health care facility levels across all WHO regions

25 November 2024

**[Considerations for wastewater and environmental surveillance for monkeypox virus: Interim guidance](#)**

.....

.....

**USA – HHS, FDA, CDC**

**HHS**

*[News](#)*

**[Statement by Assistant Secretary for Health Admiral Rachel Levine on World AIDS Day 2024](#)**

November 29, 2024 *News Release*

**FDA**

*[Press Announcements](#)*

*No new digest content identified.*

**FDA VRBPAC**

*[Advisory Committee Calendar](#)*

**[Vaccines and Related Biological Products Advisory Committee December 12, 2024 Meeting Announcement - 12/12/2024](#)**

**CDC/ACIP [U.S.] [to 30 Nov 2024]**

<http://www.cdc.gov/media/index.html>

*[Latest News](#)*

*No new digest content identified.*

**[ACIP Meetings](#)**

*[Next ACIP Meeting](#)*

February 26-27, 2025

**MMWR Weekly**

<https://www.cdc.gov/mmwr/index2024.html>

**November 28, 2024 / No. 47**

**[PDF of this issue](#)**

- [Progress Toward UNAIDS Global HIV Pre-Exposure Prophylaxis Targets: CDC-Supported Oral Pre-Exposure Prophylaxis — 37 Countries, 2017–2023](#)
- [Notes from the Field: Increase in Diagnoses of Human Parvovirus B19–Associated Aplastic Crises in Children and Adolescents with Sickle Cell Disease — Atlanta, Georgia, December 14, 2023–September 30, 2024](#)

.....

.....

## Europe

### European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

#### **Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 November 2024**

Doxycycline: currently available evidence not supporting link with risk of suicidality  
29 November 2024

#### **European Shortages Monitoring Platform enables better monitoring of shortages in the EU**

Marketing authorisation holders can now use the platform to report shortages of centrally authorised human medicines.  
28 November 2024

### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

#### **New ECDC Management Board Chair and Deputy Chair Elected**

29 Nov 2024

#### **Wastewater poliovirus detections in the EU call for continued strong surveillance and high vaccination coverage rates**

29 Nov 2024

#### **Underdiagnosis and late HIV diagnoses are holding back progress to end AIDS in the European Region**

28 Nov 2024

#### **New genomic surveillance studies reveal circulation of multidrug-resistant Enterobacterales in Europe**

25 Nov 2024

.....

.....

### Africa CDC [to 30 Nov 2024]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

#### **Strengthening Africa's Fight Against Mpox: A Unified Surveillance Protocol**

29 November 2024

#### **Request for Bids: Supply and Deliver Promotional Materials for Africa CDC**

28 November 2024

*Press Releases*

#### **Africa CDC Launches a Continental Blueprint to Combat Endemic and Neglected Tropical Diseases**

Addis Ababa, Ethiopia, 28 November 2024 – Africa Union Member States have endorsed a new strategic plan at to tackle endemic diseases across the African continent. The Africa Centres for Disease

Control and Prevention (Africa CDC) convened a key workshop from November 27–29, 2024, in Addis Ababa to launch the new strategy with an emphasis on integrated health systems, prioritising preventing and controlling major health threats such as HIV/AIDS, malaria, tuberculosis (TB), hepatitis, and neglected tropical diseases (NTDs)...

*Reviews*

### **Protecting Kids: Mpox Guidelines for Schools**

25 November 2024

.....  
.....

### **China CDC+**

<http://www.chinacdc.cn/en/>

### **National Health Commission of the People's Republic of China** [to 30 Nov 2024]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

### **National Medical Products Administration – PRC** [to 30 Nov 2024]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

### **China CDC**

#### **CCDC Weekly Reports: Current Volume (6)**

**2024-11-29 / No. 48cccWORLD AIDS DAY ISSUE**

#### **PDF of this issue**

- Foreword: Prioritizing the People in HIV Prevention: Transforming Data into Effective Policies and Actions
- Vital Surveillances: Evolution of HIV Epidemic and Emerging Challenges — China, 1989–2023
- Vital Surveillances: National and Regional Molecular Epidemiology of HIV-1 — China, 2004–2023
- Vital Surveillances: Survival of People Living with HIV/AIDS from Pre-ART Era to Treat-all Era — China, 1985–2022
- Preplanned Studies: An Index–Contact Paired Data Analysis on Sexual Contact Tracing Outcomes of HIV-Infected Individuals — Yunnan Province, China, 2022–2024
- Methods and Applications: Study on the Technical Parameters for Estimating HIV-1 Incidence by Using a Recombinant Antigen-based Capture Enzyme Immunoassay — China

.....  
.....

### ***Contents [click to move among sections]***

:: *Milestones, Perspectives*

:: *WHO*

:: *Organization Announcements*

:: *Journal Watch*

:: *Pre-Print Servers*

.....  
.....

## **Organization Announcements**

**Paul G. Allen Frontiers Group** [to 30 Nov 2024]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified*

**BMGF - Gates Foundation** [to 30 Nov 2024]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

*No new digest content identified*

**Bill & Melinda Gates Medical Research Institute** [to 30 Nov 2024]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 30 Nov 2024]

<https://carb-x.org/>

*News*

11.26.2024 |

**[CARB-X and CHAI partner to sharpen AMR response, tackle gonorrhea in low- and middle-income countries](#)**

CARB-X and the Clinton Health Access Initiative (CHAI) are partnering to evaluate the clinical needs and address market barriers for diagnostic, preventative, and therapeutic interventions targeting gonorrhea infections in low- and middle-income countries.

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 30 Nov 2024]

<http://cepi.net/>

*CEPI News*

*No new digest content identified.*

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 30 Nov 2024]

<https://cioms.ch/>

*News; Publications; Events*

**[CIOMS Real-world data report webinar](#)**

Online - December 3, 2024

This webinar introduces and explains the main concepts of the CIOMS report on Real-world data and real-world evidence in regulatory decision making. <https://doi.org/10.56759/kfxh6213> Registration is recommended as places will be limited. [Register Now](#)

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 30 Nov 2024]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 30 Nov 2024]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 30 Nov 2024]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News 28 November 2024*

[Namibia joins EDCTP Association](#)

**Emory Vaccine Center** [to 30 Nov 2024]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 30 Nov 2024]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Evidence Aid** [to 30 Nov 2024]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

[Evidence Aid: Final farewell – 31 October 2024](#)

[www.evidenceaid.org](http://www.evidenceaid.org)

When we announced the news of our closure back in July, we hoped that Evidence Aid summaries would remain accessible and free of charge beyond closure of the charity. We are delighted to be able to announce that from now, the International Rescue Committee are hosting the website, [evidenceaid.org](http://evidenceaid.org) and continue to make much of Evidence Aid's existing material available to the public. Should you have any questions relating to the website after 31 October, please contact [airbel@rescue.org](mailto:airbel@rescue.org).

**Fondation Merieux** [to 30 Nov 2024]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 30 Nov 2024]

<https://www.gavi.org/>

*Press Releases*

28 November 2024

**[Sir Mo Farah joins Members of Parliament to shine a light on the UK's critical role in ensuring vaccine equity](#)**

**GE2P2 Global Foundation** [to 30 Nov 2024]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – October 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 12 Nov 2024 – Issue 25](#)

**GHIT Fund** [to 30 Nov 2024]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 30 Nov 2024]

<https://www.theglobalfund.org/en/news/>

*News Releases*

26 November 2024

**[Global Fund Board Takes Unprecedented Set of Decisions to Strengthen Sustainability and Gears Up for Eighth Replenishment](#)**

The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) held its 52nd meeting last week in Lilongwe, Malawi. The country was selected to host the event in recognition of its remarkable progress against HIV, tuberculosis...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 30 Nov 2024]

<https://www.glopid-r.org/news/>

*news*

**[GloPID-R participates at the WHO HUB for Pandemic and Epidemic Intelligence](#)**

November 29, 2024

**Hilleman Laboratories** [to 30 Nov 2024]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 30 Nov 2024]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 30 Nov 2024]

<https://www.humanimmunomeproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 30 Nov 2024]

<https://www.iavi.org/>

*Scientific Publications*

**[Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial](#)**

**INSERM** [to 30 Nov 2024]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

26 November 2024

**[ICMRA Rare Disease Workshop Report](#)**

26 November 2024

**[Facilitating Platform Clinical Trials During Global Public Health Emergencies](#)**

... This paper contains three main sections:

- Trial design and conduct considerations. This will include a discussion of key trial characteristics, such as developing protocol elements that need to be considered when conducting a platform trial during a pandemic, including specific design elements;
- Regulatory considerations including addressing certain perceived barriers and enablers;
- A brief discussion of certain lessons learnt from the COVID-19 pandemic.

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 30 Nov 2024]

<https://www.ich.org/>

*News/Pubs/Press Releases [Selective]*

25 November 2024

**[PQKM Task Force RFI](#)**

Release of ICH Pharmaceutical Quality Knowledge Management (PQKM) Task Force Request for Information (RFI) on its initial assessment for a secure, standardised technology platform.

**ICRC** [to 30 Nov 2024]

<https://www.icrc.org/en/whats-new>



*What's New [Selected]*

**China: Journalists discuss impact of misinformation and media's role during humanitarian crises**

*News release 29-11-2024*

**Israel-Lebanon: Ceasefire an encouraging step for region exhausted by conflict**

*News release 27-11-2024*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 30 Nov 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*No new digest content identified.*

**Institut Pasteur** [to 30 Nov 2024]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 30 Nov 2024]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

*Events 5 December 2024*

**Science-policy synergies for the Biological Weapons Convention**

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

*No new digest content identified.*

**IVAC** [to 30 Nov 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

**Now Available: 2024 PDPR**

The 2024 edition of IVAC's Pneumonia and Diarrhea Progress Reports provides an analysis of 10 key indicators in the 15 countries with the greatest burden of under-five pneumonia and diarrhea deaths in young children.

[Download Here](#)

**IVI** [to 30 Nov 2024]

<http://www.ivi.int/>

*IVI News & Announcements*

**IVI and Government of Kenya sign MOU to establish AVEC Africa Project Office in Nairobi**

November 26, 2024

**IVI and Government of Rwanda sign Host Country Agreement for IVI's Africa Regional Office**

November 25, 2024

**Johns Hopkins Center for Health Security** [to 30 Nov 2024]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 30 Nov 2024]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Gaza-Israel war*

**Obstacles to essential supplies deepen Gaza's catastrophic humanitarian and medical situation**

Press Release 29 Nov 2024

*Mozambique*

**A personal commitment to HIV care in Mozambique**

Project Update 29 Nov 2024

*Lebanon*

**War and economic strain worsen health conditions in Lebanon**

Project Update 26 Nov 2024

**National Academy of Medicine - USA** [to 30 Nov 2024]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]- USA** [to 30 Nov 2024]

<https://www.nationalacademies.org/newsroom>

*News*

*No new digest content identified.*

**National Vaccine Program Office - U.S. HHS** [to 30 Nov 2024]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 30 Nov 2024]

<http://www.nih.gov/>

*News Releases*

*No new digest content identified.*

**PATH** [to 30 Nov 2024]

<https://www.path.org/media-center/>

*Newsroom*

*Latest News & Press Releases*

*No new digest content identified.*

**Sabin Vaccine Institute** [to 30 Nov 2024]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 30 Nov 2024]

<http://www.unaids.org/en>

*News, Stories, Updates*

*Press release*

**[UNAIDS report shows that upholding human rights is vital for ending the AIDS pandemic](#)**

GENEVA, 26 November 2024— Ahead of World AIDS Day (1 December), a [new report by UNAIDS](#) shows that the world can meet the agreed goal of ending AIDS as a public health threat by 2030 – but only if leaders protect the human rights of everyone living with and at risk of HIV. The report’s message is summed up in its title: “Take the rights path to end AIDS”.

**UNICEF** [to 30 Nov 2024]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*News note 29 November 2024*

**[FAST FACTS: Critical gains in HIV response, but adolescents - especially girls - remain disproportionately affected, UNICEF warns on World AIDS Day](#)**

NEW YORK, 29 November 2024 – While there has been a notable decline in new HIV infections among children and adolescents globally over the past decade, adolescent girls still struggle to access tailored prevention services and support, according to the latest available estimates. Without urgent action to address ...

**Unitaid** [to 30 Nov 2024]

<https://unitaid.org/>

*Featured News*

*News releases*

**[Unitaid invests US\\$22m to accelerate access to lenacapavir, a groundbreaking new HIV prevention drug](#)**

28 November 2024

**Vaccine Equity Cooperative [nee Initiative]** [to 30 Nov 2024]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 30 Nov 2024]

<https://www.vaccineacceptance.org/>

*Social & Behavioral Research Grants*

[Get to Know Three of our 2024-2025 Grant Partners \(Part 2\)](#)

November 27, 2024

**Vaccine Confidence Project** [to 30 Nov 2024]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 30 Nov 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 30 Nov 2024]

<https://wellcome.org/news/all>

*News. Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 30 Nov 2024]

<https://www.wistar.org/news/press-releases>

*Press Releases*

November 27, 2024

[The Wistar Institute Awarded \\$2 Million RACP Grant from Shapiro Administration for New Center for Advanced Therapeutics](#)

PHILADELPHIA — (Nov. 27, 2024) — Governor Josh Shapiro’s Administration, through the Commonwealth of Pennsylvania Redevelopment Assistance Capital Program (RACP), has granted The Wistar Institute \$...

**World Bank** [to 30 Nov 2024]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 30 Nov 2024]

<https://www.wfpha.org/>

*Blog, Events*

*No new digest content identified.*

**World Medical Association [WMA]** [to 30 Nov 2024]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

**The World Medical Association urges global commitment for a just Plastic Treaty to safeguard human and planetary health**

25.11.2024

**World Organisation for Animal Health [OIE]** [to 30 Nov 2024]

<https://www.oie.int/>

*Press Releases, Statements*

*No new digest content identified.*

.....

.....

**ARM [Alliance for Regenerative Medicine]** [to 30 Nov 2024]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 30 Nov 2024]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest announcements identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 30 Nov 2024]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest announcements identified.*

**ICBA – International Council of Biotechnology Associations** [to 30 Nov 2024]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

**IFPMA** [to 30 Nov 2024]

<https://ifpma.org/>

*News, Statements [Selected]*

*Press release 26 Nov 2024*

**Roche Chief Executive Dr. Thomas Schinecker announced as President of global pharmaceutical industry trade association, IFPMA**

**International Alliance of Patients' Organizations – IAPO** [to 30 Nov 2024]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

### **International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

#### **[INC-5 opening statement: Health industry support for a plastics instrument \(November 2024\)](#)**

25 NOVEMBER 2024, BUSAN, SOUTH KOREA – This statement is delivered on behalf of IFPMA, GSCF, and IGBA, who collectively represent innovative, generic, and biosimilars pharmaceutical companies, as well as consumer healthcare manufacturers.

### **PhRMA [to 30 Nov 2024]**

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....  
.....

### ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

#### **AstraZeneca**

*Press Releases - No new digest announcements identified*

#### **Bavarian Nordic**

*Latest News - No new digest announcements identified*

#### **Bharat Biotech**

*Press Releases - No new digest announcements identified*

#### **BioCubaFarma – Cuba**

*Últimas Noticias - No new digest announcements identified*

#### **Biological E**

*News - No new digest announcements identified*

#### **BioNTech**

*Press Releases - No new digest announcements identified*

#### **Boehringer**

*Press Releases*

#### **[Boehringer Ingelheim launches EURICAN® L4 vaccine, offering outstanding protection against leptospirosis in dogs](#)**

Ingelheim, Germany, Thu, 11/28/2024 - 13:00

*Due to climate change and urbanization, dogs in Europe face an increasing risk of the potentially fatal disease leptospirosis1, which is spread through water and soil contaminated by Leptospira bacteria.*

#### **CanSinoBIO**

*News - Website not responding at inquiry*

## **CIGB**

Latest News - No new digest announcements identified.

## **Cinnagen**

Recent News - No new digest announcements identified.

## **Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

## **Curevac**

News - No new digest announcements identified.

## **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

## **GSK**

Press releases for media

27 November 2024

### **[GSK's fully liquid Menveo meningococcal vaccine approved by European Commission](#)**

- New fully liquid presentation means reconstitution is not needed before use
- Formulation supports simplification of vaccination process against invasive meningococcal disease (IMD)
- IMD is an unpredictable but serious illness that can cause life-threatening complications

## **EuBiologics, S Korea**

News - No new digest announcements identified.

## **IMBCAMS, China**

Home - Website not responding at inquiry.

## **Janssen/JNJ**

Press Releases - No new digest announcements identified.

## **Merck**

News releases - No new digest announcements identified

## **Moderna**

Press Releases - No new digest announcements identified

## **Nanogen**

News - No new digest announcements identified

## **Novartis**

News - No new digest announcements identified.

## **Novavax**

Press Releases - No new digest announcements identified.

## **Pfizer**

Recent Press Releases - No new digest announcements identified.



## **R-Pharm**

<https://rpharm-us.com/index.php>

*[No news or media page identified]*

## **Sanofi Pasteur**

[Press Releases](#) - No new digest announcements identified.

## **Sinopharm/WIBPBIBP**

[News](#) - No new digest announcements identified *[English translation function inoperable]*

## **Sinovac**

[Press Releases](#) - No new digest announcements identified.

## **SK Biosciences**

[Press Releases](#) - No new digest announcements identified.

## **Takeda**

[Newsroom](#) - No new digest announcements identified.

## **Valneva**

[Press Releases](#)

November 26, 2024

[Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA](#)

*To potentially include adolescents and antibody persistence up to two years*

## **Vector State Research Centre of Virology and Biotechnology**

[Home](#) - *[Website not responding [404 error]]*

## **WestVac Biopharma**

[Media](#) - *Website not responding at inquiry.*

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) *[No News/Announcements page identified]*

.....

.....

## ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

## ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content

supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 15, 2023 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 26, Number 11: E823-895

<https://journalofethics.ama-assn.org/issue/peace-health-care>

#### ***Peace in Health Care***

Clinicians are carefully trained to incorporate and routinize what they do together every day, over and over again: health care professionalism has always been and is a practice. While so-called “medical shows” glamorize high-stakes, emotional health care situations, skilled clinicians generally strive to mitigate crises and control any variables they can, restore homeostasis, and promote stability and wellness in the lives of ill, injured patients. As a culture, we probably do not benefit much when health care organizations are misappropriated and misrepresented as sites of dramatic entertainment. In reality, patients, their loved ones, and their clinicians need health care organizations to be places of peace. This theme issue investigates what it means to establish and maintain health care as an enterprise known less for stress and more for healing.

### **American Journal of Human Genetics**

Nov 07, 2024 Volume 111 Issue 11p2307-2582

<https://www.cell.com/ajhg/current>

*Articles*

[Reviewed earlier]

### **American Journal of Infection Control**

November 2024 Volume 52 Issue 11 p1227-1344

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

November 2024 Volume 67 Issue 5 p641-802

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

November 2024 114(11)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 111 (2024): Issue 5 (Nov 2024)

<https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.111.issue-5.xml>

*Articles*

[Reviewed earlier]

### **Annals of Internal Medicine**

November 2024 Volume 177, Issue 11

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

### **Artificial Intelligence – An International Journal**

Volume 336 November 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/336/suppl/C>

[Reviewed earlier]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 30 Nov 2024)

[No new digest content identified]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 30 Nov 2024)

[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 30 Nov 2024)

#### **[Clinical characteristics and booster vaccine effectiveness of the Omicron variant](#)**

*Although many people received the COVID-19 vaccine, shortly after the Chinese government announced that the three-year COVID-19 restrictions were being eased, the first large number of Omicron infections appea...*

Authors: Lijun Sun, Biye Zhou, Yijia Guo, Yufei Huang, Zihui Tang, Zhaojun Wu, Yuwei Li, Liping Zhao, Yi Shan, Xiaolong Xu and Hui Jiang

Citation: BMC Infectious Diseases 2024 24:1351

Content type: Research Published on: 26 November 2024

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 30 Nov 2024)

#### **[Community engagement conduct for genetics and genomics research: a qualitative study of the experiences and perspectives of key stakeholders in Uganda](#)**

*Community engagement (CE) is one of the key strategies to optimize ethical integrity in research. However, the knowledge base on how CE should be effectively and ethically conducted, particularly for genetics ...*

Authors: Harriet Nankya, Vincent P. Alibu, Enock Matovu, Edward Wamala and John Barugahare

Citation: BMC Medical Ethics 2024 25:141

Content type: Research Published on: 27 November 2024

### **Ethical issues in genomics research in persons with Alzheimer's Disease/Alzheimer's Disease-related dementia (AD/ADRD): a systematic review**

*Given the growing number of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) genomics research projects and the vulnerabilities of study participants, it is critical to evaluate the literature...*

Authors: Aminu Yakubu, Isaac Adededeji, Oluchi C. Maduka, Ayodele Jegede and Clement Adebamowo

Citation: BMC Medical Ethics 2024 25:138

Content type: Systematic Review Published on: 25 November 2024

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 30 Nov 2024)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 30 Nov 2024)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 30 Nov 2024)

### **Trends and inequalities in BCG immunisation coverage among one-year-olds in Sierra Leone, 2008–2019**

*Bacillus Calmette-Guérin (BCG) vaccination is a cornerstone of childhood immunisation programs, protecting against tuberculosis (TB), a major public health concern. Sierra Leone, a West African nation, faces c...*

Authors: Augustus Osborne, Florence Gyembuzie Wongnaah, Camilla Bangura and Bright Opoku Ahinkorah

Citation: BMC Public Health 2024 24:3342

Content type: Research Published on: 30 November 2024

### **Conspiracy narratives and vaccine hesitancy: a scoping review of prevalence, impact, and interventions**

*Believing conspiracy narratives is frequently assumed to be a major cause of vaccine hesitancy, i.e., the tendency to forgo vaccination despite its availability. In this scoping review, we synthesise and critique...*

Authors: Frederike Taubert, Georg Meyer-Hoeven, Philipp Schmid, Pia Gerdes and Cornelia Betsch

Citation: BMC Public Health 2024 24:3325

Content type: Systematic Review Published on: 29 November 2024

**Parental vaccine hesitancy toward routine childhood immunizations and COVID-19 vaccines in Japan: A cross-sectional study**

*This study aimed to elucidate the prevalence and characteristics of parental vaccine hesitancy towards routine infant immunizations and COVID-19 vaccines in Japan.*

Authors: Aya Saitoh and Yugo Shobugawa

Citation: BMC Public Health 2024 24:3303

Content type: Research Published on: 27 November 2024

**The present value of human life losses associated with COVID-19 and likely productivity losses averted through COVID-19 vaccination in Madagascar**

*As of 3 March 2023, Madagascar had reported 1,422 deaths from COVID-19. Up to now, there hasn't been a study to estimate the Total Present Value of Human Life lost ...*

Authors: Laurent Musango, Vatsiharizandry Mandrosovololona, Fidiniaina Mamy Randriatsarafara, Volahanta Malala Ranarison, Joses Muthuri Kirigia and Claude Arsène Ratsimbaoa

Citation: BMC Public Health 2024 24:3296

Content type: Research Published on: 27 November 2024

**COVID-19 vaccination, perceptions about the vaccine and willingness to take the vaccine among unvaccinated individuals at two Ugandan border points of entry**

*A recent systematic review shows high COVID-19 vaccine effectiveness in fully-vaccinated people in Africa. However, vaccine uptake has varied across populations. We assessed the uptake, perceptions of and will...*

Authors: Joseph K. B. Matovu, Rebecca Nuwematsiko, Christine Aanyu, Lilian Tabwenda, Tom Okade, David Musoke and Esther Buregyeya

Citation: BMC Public Health 2024 24:3308

Content type: Research Published on: 27 November 2024

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 30 Nov 2024)

[No new digest content identified]

**BMJ Evidence-Based Medicine**

December 2024 - Volume 29 - 6

<https://ebm.bmj.com/content/29/6>

[Reviewed earlier]

**BMJ Global Health**

October 2024 - Volume 9 - 10

<https://gh.bmj.com/content/9/10>

[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 102(11); 2024 Nov 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/471305/>

[Reviewed earlier]

**Cell**

Nov 14, 2024 Volume 187 Issue 23 p6415-6784

<https://www.cell.com/cell/current>

[Reviewed earlier]

**Child Care, Health and Development**

Volume 50, Issue 6 November 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**

Volume 116, Issue 5 Pages: 1143-1351 November 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

**Clinical Therapeutics**

November 2024 Volume 46 Issue 11 p825-940

<http://www.clinicaltherapeutics.com/current>

[New issue; No digest content identified]

**Clinical Trials**

Volume 21 Issue 6, December 2024

<https://journals.sagepub.com/toc/ctja/21/6>

[Reviewed earlier]

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 30 Nov 2024]

[No new digest content identified]

**Contemporary Clinical Trials**

Volume 146 November 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/146/suppl/C>

[Reviewed earlier]

**The CRISPR Journal**

Volume 7, Issue 5 / October 2024

<https://www.liebertpub.com/toc/crispr/7/5>

[Reviewed earlier]

**Current Genetic Medicine Reports**

Volume 11, Issue 3-4 December 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-3>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 40, Issue 11 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

December 2024 - Volume 37 - Issue 6

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 30 Nov 2024]

[No new digest content identified]

### **Developing World Bioethics**

Volume 24, Issue 3 Pages: 135-261 September 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

### **Development Policy Review**

Volume 42, Issue 6 November 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 48, Issue 4 October 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/4>

[Reviewed earlier]

### **EMBO Reports**



Volume 25 Issue 11 8 November 2024  
<https://www.embopress.org/toc/14693178/current>  
[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 30, Number 11—November 2024  
<http://wwwnc.cdc.gov/eid/>  
[Reviewed earlier]

### **Epidemics**

Volume 48 September 2024  
<https://www.sciencedirect.com/journal/epidemics/vol/48/suppl/C>  
[Reviewed earlier]

### **Epidemiology and Infection**

Volume 152 - 2024  
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>  
[Reviewed earlier]

### **Ethics & Human Research**

Volume 46, Issue 6 Pages: 1-35 November–December 2024  
<https://onlinelibrary.wiley.com/toc/25782363/current>  
***Data monitoring committee insights / Ethics reviews and AI tools***  
[Reviewed earlier]

### **Ethics & International Affairs**

Volume 38 - Issue 2 - Summer 2024  
<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>  
[New issue; No digest content identified]

### **Ethics, Medicine and Public Health**

Volume 32 2024  
<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>  
[Reviewed earlier]

### **The European Journal of Public Health**

Volume 34, Issue 5, October 2024  
<https://academic.oup.com/eurpub/issue/34/5>  
[Reviewed earlier]

### **Expert Review of Vaccines**

Vol 23 (1) 2023  
<https://www.tandfonline.com/toc/ierv20/current>  
[Reviewed earlier]

**Foreign Affairs**

November/December 2024 Volume 103, Number 6

<https://www.foreignaffairs.com/issues/2023/103/6>

[Reviewed earlier]

**Forum for Development Studies**

Volume 51, 2024 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

**Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237>

[Accessed 30 Nov 2024]

[No new digest content identified]

**Genetics in Medicines**

Volume 26, Issue 11 November 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/11>

[Reviewed earlier]

**Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 30 Nov 2024]

[No new digest content identified]

**Global Health Action**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**

Vol. 12, No. 5 October 29, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

**Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 30 Nov 2024]

[No new digest content identified]

### **Global Public Health**

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 30 Nov 2024]

[No new digest content identified]

### **Health and Human Rights**

Volume 26, Issue 1, June 2024

<https://www.hhrjournal.org/volume-26-issue-1-june-2024/>

***SPECIAL SECTION – COMMEMORATING 30 YEARS***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 19 - Issue 3 - July 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

*Article*

**[From speculative to real: community attitudes towards government COVID-19 vaccine mandates in Western Australia from May 2021 to April 2022](#)**

Katie Attwell, Leah Roberts, Marco Rizzi

Published online by Cambridge University Press:

20 May 2024, pp. 387-406

### **Health Policy and Planning**

Volume 39, Issue 9, November 2024

<https://academic.oup.com/heapol/issue/39/9>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 30 Nov 2024]

[No new digest content identified]

### **Human Gene Therapy**

Volume 35, Issue 21-22 / November 2024

<https://www.liebertpub.com/toc/hum/35/21-22>

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

**Immunity**

Nov 12, 2024 Volume 57 Issue 11 p2483-2704

<https://www.cell.com/immunity/current>

[Reviewed earlier]

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 30 Nov 2024]

[No new digest content identified]

**Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 30 Nov 2024]

[No new digest content identified]

**International Health**

Volume 16, Issue 6, November 2024

<https://academic.oup.com/inthealth/issue/16/6>

[Reviewed earlier]

**International Human Rights Law Review**

Volume 13 (2024): Issue 1 (Jun 2024):

<https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml>

***Special Issue on Inter-State Communications***

*Table of Contents*

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol. 11 No. 11 (2024): November 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/118>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 53, Issue 5, October 2024

<https://academic.oup.com/ije/issue/53/5>

[Reviewed earlier]

## **International Journal of Human Rights in Healthcare**

Volume 17 Issue 4 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4>

*Table of contents*

[Reviewed earlier]

## **JAMA**

November 26, 2024, Vol 332, No. 20, Pages 1685-1768

<https://jamanetwork.com/journals/jama/currentissue>

*Viewpoint*

### **[AIDS in Africa—Impact of Research-The 2024 Lasker-Bloomberg Public Service Award](#)**

Quarraisha Abdool Karim, PhD; Salim S. Abdool Karim, MBChB, PhD

has audio

*JAMA*. 2024;332(20):1699-1700. doi:10.1001/jama.2024.18271

In this Viewpoint, 2024 Lasker-Bloomberg Public Service Award winners Quarraisha Abdool Karim and Salim S. Abdool Karim discuss their journey in AIDS research in South Africa and the local and global health impact of this research.

## **JAMA Health Forum**

November 2024, Vol 5, No. 11

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

## **JAMA Pediatrics**

November 2024, Vol 178, No. 11, Pages 1089-1234

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

## **JBİ Evidence Synthesis**

November 2024 - Volume 22 - Issue 11

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

## **Journal of Adolescent Health**

November 2024 Volume 75 Issue 5 p691-844

<https://www.jahonline.org/current>

[Reviewed earlier]

## **Journal of Artificial Intelligence Research**

Vol. 81 (2024)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

### **Journal of Community Health**

Volume 49, Issue 5 October 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-5>

[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 172 January 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/172/suppl/C>

*Research article Abstract only*

#### **Poverty mapping in the age of machine learning**

Paul Corral, Heath Henderson, Sandra Segovia

Article 103377

### **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

*Research article*

#### **Public Perspectives on Consent for and Governance of Biobanking in Japan**

Masanori Oikawa, Yoshiyuki Takimoto

Restricted access First published September 27, 2024pp. 208–219

### **Journal of Epidemiology & Community Health**

November 2024 - Volume 78 - 11

<https://jech.bmj.com/content/78/11>

[Reviewed earlier]

### **Journal of Evidence-Based Medicine**

Volume 17, Issue 3 Pages: 469-687 September 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

### **Journal of Global Ethics**

Volume 20, Issue 2 (2024)

<http://www.tandfonline.com/toc/rjge20/current>

#### **Special Issue: Climate Justice and the Global Development Crisis.**

*Guest Editors: Anna Malavisi, Tom Hilde, and Krushil Watene*

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 35, Number 4, November 2024

<https://muse.jhu.edu/issue/53739>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 26, Issue 5 October 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-5>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 22, 2024 \_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of International Development**

Volume 36, Issue 8 Pages: 1-3156 November 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

**Journal of Medical Ethics**

November 2024 - Volume 50 - 11

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**The Journal of Pediatrics**

Volume 274 November 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/274/suppl/C>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

**Journal of Public Health Management & Practice**

November/December 2024 - Volume 30 - Issue 6



<https://journals.lww.com/jphmp/pages/currenttoc.aspx>  
[Reviewed earlier]

**Journal of Public Health Policy**

Volume 45, issue 3, September 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-3>  
[Reviewed earlier]

**Journal of the Royal Society – Interface**

November 2024 Volume 21 Issue 220

<https://royalsocietypublishing.org/toc/rsif/current>  
[Reviewed earlier]

**Journal of Travel Medicine**

Volume 31, Issue 7, October 2024

<https://academic.oup.com/jtm/issue>  
[Reviewed earlier]

**Journal of Virology**

Volume 98 Number 9 September 2024

<http://jvi.asm.org/content/current>  
[Reviewed earlier]

**The Lancet**

Nov 30, 2024 Volume 404 Number 10468 p2131-2222

<https://www.thelancet.com/journals/lancet/issue/current>  
*Editorial*

**[Triumphs and threats: HIV in 2024](#)**

The Lancet

*Comment*

**[Addressing transnational exploitation and armed conflict in the response to mpox](#)**

Jirair Ratevosian, et al.

**The Lancet Child & Adolescent Health**

Nov 2024 Volume 8 Number 11 p773-842, e16

<https://www.thelancet.com/journals/lanchi/issue/current>  
[Reviewed earlier]

**Lancet Digital Health**

Nov 2024 Volume 6 Number 11 e772-e878

<https://www.thelancet.com/journals/landig/issue/current>  
[Reviewed earlier]

**Lancet Global Health**

Nov 2024 Volume 12 Number 11 e1737-e1909

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Nov 2024 Volume 24 Number 11 p1177-1286, e660-e724

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Nov 2024 Volume 9 Number 11 e831-e994

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Nov 2024 Volume 12 Number 11 p837-932, e65-e74

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 28, Issue 11 November 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-11>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 44 Issue 8, November 2024

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 102, Issue 3 Pages: 517-821 September 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Molecular Therapy**

Nov 06, 2024 Volume 32 Issue 11 p3747-4162

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

**Nature**

Volume 635 Issue 8040, 28 November 2024

<https://www.nature.com/nature/volumes/635/issues/8039>

*Editorial* 26 Nov 2024

**[Act now to stop millions of research papers from disappearing](#)**

Digital preservation is not keeping up with the growth of scholarly knowledge. Recognizing its causes is the first step to securing records everywhere for future generations.

**Nature Biotechnology**

Volume 42 Issue 11, November 2024

<https://www.nature.com/nbt/volumes/42/issues/11>

[Reviewed earlier]

**Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 30 Nov 2024)

[No new digest content identified]

**Nature Genetics**

Volume 56 Issue 11, November 2024

<https://www.nature.com/ng/volumes/56/issues/11>

[Reviewed earlier]

**Nature Human Behaviour**

Volume 8 Issue 11, November 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/11>

[New issue; No digest content identified]

**Nature Medicine**

Volume 30 Issue 11, November 2024

<https://www.nature.com/nm/volumes/30/issues/11>

[Reviewed earlier]

**Nature Reviews Drug Discovery**

Volume 23 Issue 11, November 2024

<https://www.nature.com/nrd/volumes/23/issues/11>

[Reviewed earlier]

**Nature Reviews Genetics**

Volume 25 Issue 11, November 2024

<https://www.nature.com/nrg/volumes/25/issues/11>

[Reviewed earlier]

**Nature Reviews Immunology**

Volume 24 Issue 11, November 2024

<https://www.nature.com/nri/volumes/24/issues/11>

[Reviewed earlier]

## **New England Journal of Medicine**

Volume 391 No. 21 November 28, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

*Original Articles*

### **Effect of a Reduced PCV10 Dose Schedule on Pneumococcal Carriage in Vietnam**

Authors: Lay-Myint Yoshida, M.B., B.S., Ph.D., et al.

Published November 27, 2024

After pneumococcal disease and colonization have been controlled through vaccination campaigns, a reduced pneumococcal conjugate vaccine (PCV) schedule may be sufficient to sustain that control at reduced costs.

### **Fractional Doses of Pneumococcal Conjugate Vaccine — A Noninferiority Trial**

K.E. Gallagher and Others

Pneumococcal conjugate vaccines are an expensive component of the routine immunization schedule. Fractional-dose regimens may be one option to increase the sustainability of the vaccine program.

## **NEJM Evidence**

Volume 3 No. 10 October 2024

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

## **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 30 Nov 2024]

[New issue; No digest content identified]

## **Pediatrics**

Volume 154, Issue Supplement 3 November 2024

<https://publications.aap.org/pediatrics/issue/154/Supplement%203>

*Articles*

[Reviewed earlier]

## **PharmacoEconomics**

Volume 42, Issue 11 November 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-11>

[Reviewed earlier]

## **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 30 Nov 2024)

[No new digest content identified]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 30 Nov 2024)

[No new digest content identified]

## **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 30 Nov 2024)

### **[Timeliness of 24 childhood immunisations and evolution of vaccination delay: Analysis of data from 54 low- and middle-income countries](#)**

Nieves Derqui, Isobel M. Blake, Elizabeth J. Gray, Laura V. Cooper, Nicholas C. Grassly, Margarita Pons-Salort, Katy A. M. Gaythorpe

Research Article | published 26 Nov 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003749>

#### *Abstract*

Vaccination timeliness is often not considered among standard performance indicators of routine vaccination programmes, such as vaccination coverage, yet quantifying vaccination delay could inform policies to promote in-time vaccination and help design vaccination schedules. Here, we analysed vaccination timeliness for 24 routine childhood immunisations for 54 countries. We extracted individual vaccination status and timing from Demographic and Health Surveys data from 54 countries with surveys from 2010 onwards. Individual data was used to estimate age at vaccination for <5 year-old children. Recommended age of vaccination for each country and vaccine was compared to the age at vaccination to determine vaccination delay. The evolution of vaccination delay over time was described using estimates from different birth cohorts. To identify socio-demographic indicators associated with delayed vaccination, we used multivariable Cox regression models with country as random effect and estimated the Hazard Ratio for vaccination with each vaccine-dose for each week post recommended vaccination age. Vaccine coverage at the recommended age was highest for birth and first doses (e.g. 50.5% BCG, 18.5% DTP-D1) and lowest for later doses (e.g. 5.5% DTP-D3, 16.3% MCV-D1, 8.2% MCV-D2). Median delay was lowest for birth doses, e.g. BCG (1 week (IQR: 0 to 4)), and it increased with later doses in vaccination courses: 1 (0, 4) week for DTP-D1 versus 4 (2, 9) weeks for DTP-D3. Although the median delay for each vaccine-dose remained largely constant over time, the range of delay estimates moderately decreased. Children living in rural areas, their countries' poorer wealth quintiles and whose mothers had no formal education were more likely to receive delayed vaccinations. Although we report most children are vaccinated within the recommended age window, we found little reduction on routine immunisation delays over the last decade and that children from deprived socioeconomic backgrounds are more likely to receive delayed vaccinations.

## **PLoS Medicine**

<https://journals.plos.org/plosmedicine/>

(Accessed 30 Nov 2024)

[No new digest content identified]

## **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 30 Nov 2024)

[No new digest content identified]

## PLoS One

<http://www.plosone.org/>

[Accessed 30 Nov 2024]

### **Knowledge, attitudes, and practices towards Human Papilloma Virus and uptake of HPV vaccine: A protocol for a systematic review**

Naharin Sultana Anni, Nadia Rehman, Agatha Nyambi, Anthony Musiwa, Tatyana Graham, Roseline Dzekem Dine, Maya Stevens-Uninsky, Elizabeth Alvarez, Zain Chagla, Laura Banfield, Lawrence Mbuagbaw

Study Protocol | published 26 Nov 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0313887>

### **Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations**

Fawziah Marra, Michael Yip, Jacquelyn J. Cragg, Nirma Khatri Vadlamudi

Research Article | published 25 Nov 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0313889>

### **Knowledge, attitude, and practice towards Hepatitis B and vaccination status of pre-clinical medical students at Sylhet Women's Medical College, Bangladesh**

Ramesh Lamichhane, Pritha Adhikari, Bishnu Deep Pathak, Aashika Rai, Pratikshya Ojha, Kripa Maharjan, Hamida Sultana Ruche, Madhusudan Saha

Research Article | published 25 Nov 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0310443>

## PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 30 Nov 2024]

[No new digest content identified]

## PNAS - Proceedings of the National Academy of Sciences of the United States

November 26, 2024 vol. 121 no. 48

<https://www.pnas.org/toc/pnas/121/48>

### ***Special Feature – Half a Century of Cultural Evolution***

*Introduction* November 18, 2024

### **Half a century of quantitative cultural evolution**

Laurel Fogarty, et al.

*Research Article* November 21, 2024

### **Teacher vaccinations enhance student achievement in Pakistan: The role of role models and theory of mind**

We provide experimental evidence that role models can galvanize prosocial actions amid global crises, exemplified by the COVID-19 pandemic. In a randomized control trial comparing role models, cash incentives, and celebrity endorsements, only role models ...

Sultan Mehmood, Shaheen Naseer and Daniel L. Chen

## PNAS Nexus

Volume 3, Issue 10, October 2024

<https://academic.oup.com/pnasnexus/issue/3/10>

[Reviewed earlier]

### **Prehospital & Disaster Medicine**

Volume 39 - Issue 3 - June 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

### **Preventive Medicine**

Volume 187 October 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/187/suppl/C>

[Reviewed earlier]

### **Proceedings of the Royal Society B**

November 2024 Volume 291 Issue 2034

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

### **Public Health**

Volume 236 Pages 1-472 (November 2024)

<https://www.sciencedirect.com/journal/public-health/vol/236/suppl/C>

[Reviewed earlier]

### **Public Health Ethics**

Volume 17, Issue 1-2, April/July 2024

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Genomics**

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

### **Public Health Reports**

Volume 139 Issue 6, November/December 2024

<https://journals.sagepub.com/toc/phrg/139/6>

[Reviewed earlier]

### **Qualitative Health Research**

Volume 34 Issue 13, November 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

### **Research Ethics**

Volume 20 Issue 4, October 2024  
<http://journals.sagepub.com/toc/reab/current>  
[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>  
[Accessed 30 Nov 2024]  
[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>  
*Latest Articles*  
[No new digest content identified]

### **Risk Analysis**

Volume 44, Issue 11 Pages: 2517-2754 November 2024  
<https://onlinelibrary.wiley.com/toc/15396924/current>  
[Reviewed earlier]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>  
[Accessed 30 Nov 2024]  
[No new digest content identified]

### **Science**

Volume 386| Issue 6725| 29 Nov 2024  
<https://www.science.org/toc/science/current>  
*Editorial*

#### **[A new vision for American science](#)**

BY Sudip S. Parikh, Marcia K. McNutt, Darío Gil  
28 Nov 2024

### **Science and Engineering Ethics**

Volume 30, Issue 6 December 2024  
<https://link.springer.com/journal/11948/volumes-and-issues/30-6>  
[Reviewed earlier]

### **Science Translational Medicine**

Volume 16| Issue 775| 27 Nov 2024  
<https://www.science.org/toc/stm/current>  
[New issue; No digest content identified]

### **Scientific Reports**



<https://www.nature.com/srep/articles?type=article>

[Accessed 30 Nov 2024]

[No new digest content identified]

### **Social Science & Medicine**

Volume 360 November 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/360/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 30 Nov 2024]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 45, Issue 6 December 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-6>

[New issue; No digest content identified]

### **Travel Medicine and Infectious Diseases**

Volume 61 September–October 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/61/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 29, Issue 11 Pages: i-iv, 923-989 November 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

### **Vaccine**

Volume 42, Issue 25 14 November 2024

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/25>

[Reviewed earlier]

### **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 30 Nov 2024]

*Open Access Article*

#### **[Evaluation of Integrated Child Health Days as a Catch-Up Strategy for Immunization in Three Districts in Uganda](#)**

by Mansoor Farahani, Tonny Tindyebwa, Nandita Sugandhi, Kirsten Ward, Youngjoo Park, Pamela Bakkabulindi, Shibani Kulkarni, Aaron Wallace, Samuel Biraro, Yvette Wibabara, Hannah Chung, Giles A. Reid, Driwale Alfred, Rita Atugonza, Elaine J. Abrams and Ledor S. Igboh

Vaccines 2024, 12(12), 1353; <https://doi.org/10.3390/vaccines12121353> (registering DOI) - 29 Nov 2024

### *Abstract*

Background: Uganda's Integrated Child Health Day (ICHD) initiative aims to improve children's access to vaccinations. Although widely used as a catch-up vaccination strategy, the effectiveness of the ICHD program in increasing immunization coverage, especially among vulnerable populations, has not been recently evaluated. This

### *Open Access Systematic Review*

#### **Determinants of COVID-19 Vaccine Acceptance and Hesitancy: A Systematic Review**

by Juliana Soares Tenório De Araújo, Felipe Mendes Delpino, Rubia Laine de Paula Andrade-Gonçalves, Francisca Bruna Arruda Aragão, Letícia Peticarrara Ferezin, Denise Alves Santos, Neemais Costa Duarte Neto, Murilo César do Nascimento, Simão Pedro Tavares Moreira, Gabriela Ferreira Ribeiro, Rayssa Francielly dos Santos Alves and Ricardo Alexandre Arcêncio

Vaccines 2024, 12(12), 1352; <https://doi.org/10.3390/vaccines12121352> - 29 Nov 2024

### *Abstract*

Background/Objectives: COVID-19 is an infectious disease whose prevention is significantly aided by vaccination, which reduces both case severity and mortality. Despite the safety and efficacy of vaccines, acceptance is not universal, and understanding of the factors influencing vaccination decisions and hesitancy remains limited. [..]

### *Open Access Article*

#### **Progress of Measles and Rubella Surveillance in the Context of Measles Elimination in the WHO Eastern Mediterranean Region, 2019–2022**

by Muhammad Farid, Kamal Fahmy, Amany Ghoniem, Md Sharifuzzaman, Quamrul Hasan, Natasha Crowcroft and Patrick O'Connor

Vaccines 2024, 12(12), 1349; <https://doi.org/10.3390/vaccines12121349> - 29 Nov 2024

### *Abstract*

In 2015, the 62nd session of the Regional Committee [RC] of the Eastern Mediterranean Region [EMR] endorsed the Eastern Mediterranean Vaccine Action Plan 2016–2020 (EMVAP) that included postponement of the measles elimination target to before 2020. However, the EMR does not have a [..]

### *Open Access Opinion*

#### **Epidemiology of Pertussis After the COVID-19 Pandemic: Analysis of the Factors Involved in the Resurgence of the Disease in High-, Middle-, and Low-Income Countries**

by Lucia F. Bricks, Juan C. Vargas-Zambrano and Denis Macina

Vaccines 2024, 12(12), 1346; <https://doi.org/10.3390/vaccines12121346> - 28 Nov 2024

### *Abstract*

Pertussis is a highly contagious bacterial disease of the respiratory tract that can be prevented by vaccination. Before the COVID-19 pandemic, the vaccine coverage rate for the third dose of a DPT-containing vaccine was 86%, with large disparities among countries. Since 2022, many [...]

### *Open Access Article*

#### **Bridging the Vaccination Equity Gap: A Community-Driven Approach to Reduce Vaccine Inequities in Polio High-Risk Areas of Pakistan**

by Imran A. Chauhadry, Sajid Bashir Soofi, Muhammad Sajid, Rafey Ali, Ahmad Khan, Syeda Kanza Naqvi, Imtiaz Hussain, Muhammad Umer and Zulfiqar A. Bhutta

Vaccines 2024, 12(12), 1340; <https://doi.org/10.3390/vaccines12121340> - 28 Nov 2024

### *Abstract*

Background: Immunization saves millions of lives, and globally, vaccines have significantly contributed to reducing mortality and morbidity due to more than 20 life-threatening illnesses. However, there are considerable disparities in vaccination coverage among countries and within populations. This study evaluates the reduction in [..]

*Open Access Conference Report*

**Antiscience, Vaccine Hesitancy, and Pandemic Responses: Highlights from the Asia Pacific Summit on Infectious Diseases and Immunization**

by Ananta Seth, Nick Sevdalis, Zulkifli Ismail, Sri Rezeki Hadinegoro, Heidi J. Larson and Tikki Pangestu  
Vaccines 2024, 12(12), 1336; <https://doi.org/10.3390/vaccines12121336> - 27 Nov 2024

**Abstract**

The recent resurgence of mpox highlights the urgent need for rethinking vaccination strategies globally, underscored by the painful memories of past public health crises where delayed responses and inequitable vaccine distribution exacerbated the spread of infectious diseases. The inaugural APIC-ADVA Asia Pacific Summit [...]

**Value in Health**

November 2024 Volume 27 Issue 11p1469-1634

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

**World Development**

Volume 183 November 2024

<https://www.sciencedirect.com/journal/world-development/vol/183/suppl/C>

[Reviewed earlier]

.....  
.....

***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

***Pre-Print Servers***

**arxiv**

<https://arxiv.org/>

[Accessed 30 Nov 2024]

[*Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

arXiv:2411.16702 [pdf, html, other]

**A Clinical Trial Design Approach to Auditing Language Models in Healthcare Settings**

Lovedeep Gondara, Jonathan Simkin

We present an audit mechanism for language models, with a focus on models deployed in the healthcare setting. Our proposed mechanism takes inspiration from clinical trial design where we posit the language model audit as a single blind equivalence trial, with the comparison of interest being the subject matter experts. We show that using our proposed method, we can follow principled sample size and power calculations, leading to the requirement of sampling minimum number of records while

maintaining the audit integrity and statistical soundness. Finally, we provide a real-world example of the audit used in a production environment in a large-scale public health network.

[arXiv:2411.16691](https://arxiv.org/abs/2411.16691) [pdf, other]

### **The Dual Impact of Artificial Intelligence in Healthcare: Balancing Advancements with Ethical and Operational Challenges**

Balaji Shesharao Ingole, Vishnu Ramineni, Nikhil Kumar Pulipeta, Manoj Jayntilal Kathiriya, Manjunatha Sughaturu Krishnappa, Vivekananda Jayaram

Journal-ref: European Journal of Computer Science and Information Technology, 12 (6), 35-45, 2024  
Print ISSN: 2054-0957 (Print)

The synchronic and diachronic study of the evolution of Artificial Intelligence (AI) unveils one prominent fact that its effect can be traced in almost all fields such as healthcare industry. The growth is perceived holistically in software, hardware implementation, or application in these various fields. As the title suggests, the review will highlight the impact of AI on healthcare possibly in all dimensions including precision medicine, diagnostics, drug development, automation of the process, etc., explicating whether AI is a blessing or a curse or both. With the availability of enough data and analysis to examine the topic at hand, however, its application is still functioning in quite early stages in many fields, the present work will endeavour to provide an answer to the question. This paper takes a close look at how AI is transforming areas such as diagnostics, precision medicine, and drug discovery, while also addressing some of the key ethical challenges it brings. Issues like patient privacy, safety, and the fairness of AI decisions are explored to understand whether AI in healthcare is a positive force, a potential risk, or perhaps both.

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 30 Nov 2024]

[No new digest content identified]

### **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 30 Nov 2024]

[Filter: All articles]

### **Towards a Social Media-based Disease Surveillance System for Early Detection of Influenza-like Illnesses: A Twitter Case Study in Wales**

Mark Drakesmith, Dimosthenis Antypas, Clare Brown, Jose Camacho-Collados, Jiao Song  
medRxiv 2024.11.11.24316812; doi: <https://doi.org/10.1101/2024.11.11.24316812> Revision

### **Shared Clinical and Immunologic Features of mRNA Vaccines: Preliminary Results from a Comparative Clinical Study**

Carlos Fierro, Nelia Sanchez-Crespo, Daniel Makrinos, Weijie Zhang, Yanbo Sun, Poonam Rohilla, Bethany Girard, Abidemi Adeniji, Anthony DiPiazza, Robert Paris  
medRxiv 2024.11.26.24318005; doi: <https://doi.org/10.1101/2024.11.26.24318005>

### **Assessing the effect of social contact structure on the impact of pneumococcal conjugate vaccines**

Anabelle Wong, Sarah C. Kramer, Daniel M. Weinberger, Matthieu Domenech de Cellès  
medRxiv 2024.08.13.24311931; doi: <https://doi.org/10.1101/2024.08.13.24311931> Revision

### **Interplay Between the Gut Microbiome and Typhoid Fever: Insights from Endemic Countries and a Controlled Human Infection Model**

Philip M. Ashton, Leonardos Mageiros, James E. Meiring, Angeziwa Chunga Chirambo, Farhana Khanam, Sabina Dongol, Happy Banda, Abhilasha Karkey, Lorena Preciado Llanes, Helena Thomaides-Brears, Malick Gibani, Nazmul Hasan Rajib, Nazia Rahman, Prasanta Kumar Biswas, Md Amirul Islam Bhuiyan, Sally Kay, Kate Auger, Olivier Seret, Nicholas R. Thomson, Andrew J. Pollard, Stephen Baker, Buddha Basnyat, John D. Clemens, Christiane Dolecek, Sarah J. Dunstan, Gordon Dougan, Robert S. Heyderman, Virginia E. Pitzer, Firdausi Qadri, Melita A. Gordon, Kathryn E. Holt, Thomas C. Darton, Strategic Typhoid Alliance Across Asia and Africa Consortium  
medRxiv 2024.09.02.24312347; doi: <https://doi.org/10.1101/2024.09.02.24312347> Revision

### **Evaluating malaria elimination strategies in military forces in Cambodia: a cluster-randomized clinical trial comparing monthly prophylaxis with focused screening and treatment**

Mariusz Wojnarski, Sidhartha Chaudhury, Threechada Boonchan, Rathvicheth Bun, Soklyda Chann, Panita Gosi, Kin Soveasna, Sokhun Song, Nillawan Buathong, Mali Ittiverakul, Sabaithip Sriwichai, Montri Arsanok, Worachet Kuntawunginn, Piyaporn Saingam, Chaiyaporn Chaisatit, Alongkot Ponlawat, Thanyalak Fansiri, Pattaraporn Vanachayangkul, Boonsong Jaichapor, Muth Sinoun, Char Meng Chuor, Thay Kheangheng, Mary So, Elizabeth Wanja, Silas Davidson, Michele Spring, Huy Rekol, Lek Dysoley, Kong Saly, Jeffrey R. Livezey, Jessica T. Lin, Philip L. Smith, Prom Satharath, Jessica E. Manning, Somethy Sok, David L. Saunders  
medRxiv 2024.11.26.24318027; doi: <https://doi.org/10.1101/2024.11.26.24318027>

### **Global solidarity in genomic surveillance improves early detection of respiratory virus threats**

Simon P.J. de Jong, Brooke E. Nichols, Anniëk de Ruijter, Edyth Parker, Vera Mitesser, Christian Happi, Menno D. de Jong, Alvin X. Han, Colin A. Russell  
medRxiv 2023.11.01.23297901; doi: <https://doi.org/10.1101/2023.11.01.23297901> Revision

### **Number of interventional clinical trials registered per million population per country worldwide**

Jonas Leth Bjerg, Dimitrinka Nikolova, Christian Gluud  
medRxiv 2024.11.22.24317736; doi: <https://doi.org/10.1101/2024.11.22.24317736>

#### *Abstract*

**Background** Historically, Sweden and Denmark have excelled in clinical trial publications per million population, but many trials have remained unpublished. Enforceable policies for trial registration before launch, made global and national clinical research assessments possible. The World Health Organisation (WHO) hosts the International Clinical Trials Registry Platform (ICTRP) for interventional clinical trials, with data from 1999.

**Objective** To find out if the retrospective or prospective trial registration activities per million population per country during the 2009 to 2022 period have improved after establishing the number of interventional clinical trials registered per million population per country during the 1999 to 2022 period.

**Methods** We used the WHO ICTRP to extract the numbers of registered interventional clinical trials. We entered data in Microsoft Excel to analyse two separate periods, 1999 to 2022 and 2009 to 2022. The second period aimed at filtering out the pickup of the registration requirements. To obtain the trial registration activity by country, we divided the number of interventional clinical trials registered by the country's population in millions. Information on population numbers originated from the World Bank, the Central Intelligence Agency World Factbook, and The National Institute of Statistics and Economic Studies (of France) as of 2022. We collected data as of 03-01-2024.

**Results** In February 2023, there were 943.113 interventional clinical trials on the ICTRP. After excluding 32.309 trials with unknown country of origin, 910.804 trials from 229 countries and territories were analysed. For countries or territories with populations over 1 million, the top five in interventional clinical trial registrations per million during 1999-2022 were Denmark, Estonia, Belgium, The

Netherlands, and Latvia. For 2009-2022, they were Denmark, Estonia, Belgium, The Netherlands, and New Zealand. The top five overall, irrespective of population, for both periods were Pitcairn, The Vatican, Tokelau, Niue, and Denmark.

Conclusions Since 1999, there has been worldwide growth in interventional trial registrations, especially among top-contributing countries. The global average stands at approximately 115 registered trials per million people from 1999 to 2022, highlighting the need for continued efforts to improve trial registration and production. Smaller Western countries lead in interventional clinical trials per million population.

### **[A global analysis of quarantine and isolation policies governing outbreak responses](#)**

Amanda Rosner, Ciara M. Weets, Rory Wilson, Rebecca Katz

medRxiv 2024.11.20.24317642; doi: <https://doi.org/10.1101/2024.11.20.24317642>

### **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

*[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-  
[No new digest content identified]*

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 30 Nov 2024]

[No new digest content identified]

\* \* \* \*

### **Think Tanks**

#### **Brookings** [to 30 Nov 2024]

<http://www.brookings.edu/>

*Research*

*No new digest content identified.*

#### **Center for Global Development** [to 30 Nov 2024]

<https://www.cgdev.org/>

*All Research*

*No new digest content identified.*

#### **Chatham House** [to 30 Nov 2024]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

#### **Council on Foreign Relations** [to 30 Nov 2024]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 30 Nov 2024]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**Kaiser Family Foundation** [to 30 Nov 2024]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

*No new digest content identified.*

**McKinsey Global Institute** [to 30 Nov 2024]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 30 Nov 2024]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 30 Nov 2024]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 30 Nov 2024]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*Commentary Nov 26, 2024*

### **[How Federal Funding Terms and Conditions Could Encourage Safe Artificial Intelligence Development](#)**

In this paper, the authors examine policy and regulatory opportunities available to the U.S. federal government to enforce safety and security requirements on artificial intelligence systems supported by U.S. government funds.

**Urban Institute** [to 30 Nov 2024]

<https://www.urban.org/publications>

**[New Research Publications - Selected](#)**

**World Economic Forum** [to 30 Nov 2024]

<https://agenda.weforum.org/press/>

*Media [Selected]*

*No new digest content identified.*



.....  
.....

## Public Consultations/Call for Inputs/Call for Papers

### Request for Information (RFI): To Inform the Development of the 2026-2030 National HIV/AIDS Strategy and the National Strategic Plans for Sexually Transmitted Infections, Vaccines, and Viral Hepatitis

US Health and Human Services Department - 10/07/2024 **Comment period ends December 6, 2024.**

\* \* \* \*  
\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*  
\* \* \* \*